Skip to main content
Mijn bibliotheek
Shop
Nieuws Boeken Tijdschriften E-learning Web-tv Video Audio
Tips voor Mijn BSL
UITGEBREID ZOEKEN
Inloggen
Top
Gepubliceerd in:
Multivariable Evaluation of Candidates for Cardiovascular Disease hoofdstuk lezen eerste hoofdstuk lezen

2013 | OriginalPaper | Hoofdstuk

46. Preventive Cardiology

Auteurs : Temilolu O. Aje, MD, MPH, Michael Miller, MD

Gepubliceerd in: Essential Cardiology

Uitgeverij: Springer New York

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Abstract

The Framingham Risk Score has been endorsed by the National Cholesterol Education Program (NCEP) to assess the 10-year risk of coronary heart disease (CHD). Updated evidence-based guidelines may also include lifetime CHD risk and/or the integration of other factors associated with increased risk (i.e., chronic renal insufficiency). The field of preventive cardiology continues to evolve as the prevalence of CHD risk factors in the population change. In this day and age when obesity and type 2 diabetes mellitus have become epidemic, never has the need for identifying areas for CHD prevention been greater. This chapter will highlight results of recently completed clinical trials and the associated advances made toward reducing primary and secondary CHD risk.
vorige hoofdstuk Cardiovascular Cell Therapy
volgende hoofdstuk Peripheral Arterial Disease
Literatuur
1.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–97.CrossRef
2.
Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA. 2007;297:611–9.PubMedCrossRef
3.
Helfand M, Buckley DI, Freeman M, Fu R, Rogers K, Fleming C, et al. Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;151:496–507.PubMedCrossRef
4.
Davidson MH, Ballantyne CM, Jacobson TA, et al. Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. J Clin Lipidol. 2011;5:338–67.PubMedCrossRef
5.
Braunwald E. Epilogue: what do clinicians expect from imagers? J Am Coll Cardiol. 2006;47(8 Suppl):101–3.CrossRef
6.
Lloyd-Jones DM, Leip EP, Larson MG, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. 2006;113:791–8.PubMedCrossRef
7.
8.
Wood D. European and American recommendations for coronary heart disease prevention. Eur Heart J. 1998;19(Suppl A):12–9.
9.
Stamler J, Stamler R, Neaton JD, et al. Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy: findings for 5 large cohorts of young adult and middle-aged men and women. JAMA. 1999;282:2012–8.PubMedCrossRef
10.
Polonsky TS, McClelland RL, Jorgensen NW, Bild DE, Burke GL, Guerci AD, et al. Coronary artery calcium score and risk classification for coronary heart disease prediction. JAMA. 2010;303:1610–6.PubMedCrossRef
11.
Greenland P, Knoll MD, Stamler J, et al. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA. 2003;290:891–7.PubMedCrossRef
12.
Kwiterovich Jr PO. Biochemical, clinical, epidemiologic, genetic, and pathologic data in the pediatric age group relevant to the cholesterol hypothesis. Pediatrics. 1986;78:349–62.PubMed
13.
Pedersen TR, Faergeman O, Kastelein JJ, Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294:2437–45.PubMedCrossRef
14.
Cannon CP, Braunwald E, McCabe CH, et al. Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;35:1495–504.CrossRef
15.
LaRosa JC, Grundy SM, Waters DD, et al. Treating to New Targets (TNT) Investigators. N Engl J Med. 2005;352:1425–35.PubMedCrossRef
16.
Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583–92.PubMedCrossRef
17.
AIM-HIGH Investigators. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol rationale and study design. The atherothrombosis intervention in metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH). Am Heart J. 2011;161:471–7.CrossRef
18.
Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255–67.PubMedCrossRef
19.
Schlant RC, Forman S, Stamler J, Canner PL. The natural history of coronary heart disease: prognostic factors after recovery from myocardial infarction in 2789 men. The 5-year findings of the coronary drug project. Circulation. 1982;66:401–14.PubMedCrossRef
20.
Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, et al. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245–55.PubMedCrossRef
21.
Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237–45.PubMedCrossRef
22.
Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341:410–8.PubMedCrossRef
23.
Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. ILLUMINATE Investigators. N Engl J Med. 2007;357:2109–22.PubMedCrossRef
24.
Barter P. Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Am J Cardiol. 2009;104(10 Suppl):10E–5E.PubMedCrossRef
25.
Cannon CP, Shah S, Dansky HM, Determining the Efficacy and Tolerability Investigators, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010;363:2406–15.PubMedCrossRef
26.
Nicholls SJ, Brewer HB, Kastelein JJ, et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA. 2011;306:2099–109.PubMedCrossRef
27.
Fayad ZA, Mani V, Woodward M, et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet. 2011;378:1547–59.PubMedCrossRef
28.
Miller M, Stone NJ, Ballantyne C, American Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011;123:2292–333.PubMedCrossRef
29.
Ginsberg HN, Elam MB, Lovato LC, ACCORD Study Group, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563–74.PubMedCrossRef
30.
Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007;115:2761–88.PubMedCrossRef
31.
A Joint Editorial Statement by the American Diabetes Association; the National Heart, Lung, and Blood Institute; the Juvenile Diabetes Foundation International; the National Institute of Diabetes and Digestive and Kidney Diseases; and the American Heart Association. Diabetes mellitus: a major risk factor for cardiovascular disease. Circulation. 1999;100:1132–3.CrossRef
32.
The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:254–9.
33.
Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557–65.PubMedCrossRef
34.
Ford ES. Body mass index, diabetes, and C-reactive protein among U.S. adults. Diabetes Care. 1999;22:1971–7.PubMedCrossRef
35.
Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in Men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–207.PubMedCrossRef
36.
Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Centers for Disease Control and Prevention; American Heart Association. Circulation. 2003;107:499–511.PubMedCrossRef
37.
Krantz DS et al. Mental stress as a trigger for myocardial ischemia and infarction. Cardiol Clin. 1996;14(2):271–87.PubMedCrossRef
38.
Yeung AC, Vekshtein VI, Krantz DS, et al. The effect of atherosclerosis on the vasomotor responses of coronary arteries to mental stress. N Engl J Med. 1991;325:1551–6.PubMedCrossRef
39.
Jain D, Shaker SM, Burg M, Wackers FJ, Soufer R, Zaret BL. Effects of mental stress on left ventricular and peripheral vascular performance in patients with coronary artery disease. J Am Coll Cardiol. 1998;31:1314–22.PubMedCrossRef
40.
Carney RM, Freedland KE, Miller GE, Jaffe AS. Depression as a risk factor for cardiac mortality and morbidity: a review of potential mechanisms. J Psychosom Res. 2002;53:897–902.PubMedCrossRef
41.
Rugulies R. Depression as a predictor for coronary heart disease. A review and meta-analysis. Am J Prev Med. 2002;23:51–61.PubMedCrossRef
42.
Musselman DL, Tomer A, Manatunga AK, et al. Exaggerated platelet reactivity in major depression. Am J Psychiatry. 1996;153:1313–7.PubMed
43.
Dention AN, Pieper CF, Rao MK, Currie MS, Harris T, Blazer DG, et al. Association of interleukin 6 and other biologic variables with depression in older people living in the community. J Am Geriatr Soc. 1999;47:6–11.
44.
Pratt LA, Ford DE, Crum RM, et al. Depression, psychotropic medication, and risk of myocardial infarction. Prospective data from the Baltimore ECA follow-up. Circulation. 1996;94:3123–9.PubMedCrossRef
45.
Zellweger MJ, Osterwalder RH, Langewitz W, Pfisterer ME. Coronary artery disease and depression. Eur Heart J. 2004;25:3–9.PubMedCrossRef
46.
O’Leary DH, Polak JF, Kronmal RA, et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med. 1999;340:14–22.PubMedCrossRef
47.
Howard G, Sharrett AR, Heiss G, et al. Carotid artery intimal-­medial thickness distribution in general populations as evaluated by B-mode ultrasound. ARIC Investigators. Stroke. 1993;24:1297–304.PubMedCrossRef
48.
Kastelein JJ, Wiegman A, de Groot E. Surrogate markers of atherosclerosis: impact of statins. Atheroscler Suppl. 2003;4:31–6.PubMedCrossRef
49.
Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. JAMA. 2004;291:1238–45.PubMedCrossRef
50.
Greenland P, LaBree L, Azen SP, et al. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA. 2004;291:210–5.PubMedCrossRef
51.
Folson AR, Kronmal RA, Detrano RC, et al. Coronary artery calcification compared with carotid intima-media thickness in the prediction o cardiovascular disease incidence. The Multi-Ethnic Study of Atherosclerosis. Arch Intern Med. 2008;168:1333–9.CrossRef
52.
Eaton SB, Konner M, Shostak M. Stone agers in the fast lane: chronic degenerative disease in evolutionary perspective. Am J Med. 1988;84:739–49.PubMedCrossRef
53.
Eaton SB, Eaton III SB, Konner MJ, Shostak M. An evolutionary perspective enhances understanding of human nutritional requirements. J Nutr. 1996;126:1732–40.PubMed
54.
Connor WE, Hoak JC, Warner ED. The effects of fatty acids on blood coagulation and thrombosis. Thromb Diath Haemorrh Suppl. 1965;17:89–102.PubMed
55.
Dietschy JM. Dietary fatty acids and the regulation of plasma low density lipoprotein cholesterol concentrations. J Nutr. 1998;128:444S–8S.PubMed
56.
Mensink RP, Katan MB. Effect of dietary trans fatty acids on high-density and low density lipoprotein cholesterol levels in healthy subjects. N Engl J Med. 1990;323:439–45.PubMedCrossRef
57.
Gillman MW, Cupples LA, Gagnon D, Millen BE, Ellison RC, Castelli WP. Margarine intake and subsequent coronary heart disease in men. Epidemiology. 1997;8:144–9.PubMedCrossRef
58.
Pietinen P, Ascherio A, Korhonen P, et al. Intake of fatty acids and risk of coronary heart disease in a cohort of Finnish men. The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. Am J Epidemiol. 1997;145:876–87.PubMedCrossRef
59.
Willett WC, Stampfer MJ, Colditz GA. Intake of trans fatty acids and risk of coronary heart disease among women. Lancet. 1993;341:581–5.PubMedCrossRef
60.
de Lorgeril M, Renaud S, Marmelle N, et al. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet. 1994;343:1454–9.PubMedCrossRef
61.
de Lorgeril M, Salen P, Martin J-L, et al. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation. 1999;99(6):779–85.PubMedCrossRef
62.
Garg A, Bantle JP, Henry RR, et al. Effects of varying carbohydrate content of diet in patients with non-insulin-dependent diabetes mellitus. JAMA. 1994;271:1421–8.PubMedCrossRef
63.
Kris-Etherton PM, Yu-Poth S, Sabate J, et al. Nuts and their bioactive constituents: effects on serum lipids and other factors that affect disease risk. Am J Clin Nutr. 1999;70(Suppl):504–11.
64.
65.
Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet. 1989;334:757–61.CrossRef
66.
Marchioli R, et al. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Lancet. 1999;354:447–55.
67.
Leaf A. Diet and sudden cardiac death. J Nutr Health Aging. 2001;5:173–8.PubMed
68.
Kris-Etherton PM, Harris WS, Appel LJ, et al. Omega-3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association. AHA Nutrition Committee. American Heart Association. Arterioscler Thromb Vasc Biol. 2003;23:151–2.PubMedCrossRef
69.
Connor SL, Connor WE. Are fish oils beneficial in the prevention and treatment of coronary artery disease? Am J Clin Nutr. 1997;66(Suppl):1020S–31S.PubMed
70.
Kowey PR, Reiffel JA, Ellenbogen KA, Naccarelli GV, Pratt CM. Efficacy and safety of prescription omega-3 fatty acids for the ­prevention of recurrent symptomatic atrial fibrillation: a randomized controlled trial. JAMA. 2010;304:2363–72.PubMedCrossRef
71.
72.
Ornish D, Brown SE, Scherwitz LW, et al. Can lifestyle changes reverse coronary heart disease? the lifestyle heart trial. Lancet. 1990;336:129–33.PubMedCrossRef
73.
Ornish D, Scherwitz LW, Billings JH, et al. Intensive lifestyle changes for reversal of coronary heart disease. JAMA. 1998;280:2001–7.PubMedCrossRef
74.
Barnard RJ, DiLauro SC, Inkeles SB. Effects of intensive diet and exercise intervention in patients taking cholesterol-lowering drugs. Am J Cardiol. 1997;79(8):1112–4.PubMedCrossRef
75.
Sacks FM, Bray GA, Carey VJ, et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med. 2009;360:859–73.PubMedCrossRef
76.
Arts I, Hollman P, Feskens E, et al. The Zutphen Elderly Study. Am J Clin Nutr. 2001;74:227–32.PubMed
77.
Knekt P, Kumpulainen J, Järvinen R, et al. Flavonoid intake and risk of chronic diseases. Am J Clin Nutr. 2002;76:560–8.PubMed
78.
Gu L, Kelm MA, Hammerstone JF. Concentrations of proanthocyanidins in common foods and estimations of normal consumption. J Nutr. 2004;134:613–7.PubMed
79.
Hu FB, Willett WC. Optimal diets for prevention of coronary heart disease. JAMA. 2002;288:2569–78.PubMedCrossRef
80.
Khan A, Safdar M, Ali Khan MM, Khattak KN, Anderson RA. Cinnamon improves glucose and lipids of people with type 2 diabetes. Diabetes Care. 2003;26:3215–8.PubMedCrossRef
81.
Anderson RA, Broadhurst CL, Polansky MM, et al. Isolation and characterization of polyphenol type-a polymers from cinnamon with insulin-like biological activity. J Agric Food Chem. 2004;52:65–70.PubMedCrossRef
82.
Paffenbargar Jr RS, Hyde RT, Wing AL, et al. The association of changes in physical activity level and other lifestyle characteristics with mortality among men. N Engl J Med. 1993;328:538–45.CrossRef
83.
84.
Tanasescu M, Leitzmann MF, Rimm EB, Willett WC, Stampfer MJ, Hu FB. Exercise type and intensity in relation to coronary heart disease in men. JAMA. 2002;288:1994–2000.PubMedCrossRef
85.
Wodlinger AM, Pieper JA. The role of clopidogrel in the management of acute coronary syndromes. Clin Ther. 2003;25:2155–81.PubMedCrossRef
86.
Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001–15.PubMedCrossRef
87.
88.
Bijnen FCH, Caspersen CJ, Feskens EJM, Saris WHM, Mosterd WL, Kromhout D. Physical activity and 10-year mortality from cardiovascular diseases and all causes. Arch Intern Med. 1998;158:1499–505.PubMedCrossRef
Harris WS. Fish oils and plasma lipid and lipoprotein metabolism in humans: a critical review. J Lipid Res. 1989;30:785–807.PubMed
Katan MB, Grundy SM, Willett WC. Beyond low fat diets. N Engl J Med. 1999;337:563–6.
Mayer EM, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol. 1996;27:517–27.PubMedCrossRef
O’Rourke RA, Brundage BH, Froelicher VF, et al. American College of Cardiology/American Heart Association Expert Consensus Document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease. J Am Coll Cardiol. 2001;36:326–40.CrossRef
Metagegevens
Titel
Preventive Cardiology
Auteurs
Temilolu O. Aje, MD, MPH
Michael Miller, MD
Copyright
2013
Uitgeverij
Springer New York
Boek
Essential Cardiology

Print ISBN: 978-1-4614-6704-5

Elektronisch ISBN: 978-1-4614-6705-2

Copyright: 2013

DOI
https://doi.org/10.1007/978-1-4614-6705-2_46